Month: May 2025

Non-Perishable Revenue Grows 15%; Gross Profit Nearly Quadruples Year-over-Year as Company Shifts Focus to Higher Margin, Shelf-Stable Offerings Strategic Product Mix Realignment Driving Operational Efficiency and Margin Expansion Conference Call to Be Held Today at 8:00 am ET. BELVIDERE, N.J., May 15, 2025 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products, today provided a business update and reported financial results for the three months ended March 31, 2025.   “Our performance in the first quarter reflects the strength of our strategic direction and the disciplined execution of our product realignment,” said Jim Kras, Chief Executive Officer of Edible Garden....

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce its first-quarter 2025 consolidated financial results and operational highlights. The Company will host an investor update call on Tuesday, May 27th at 11:00 a.m. Eastern Time, with registration instructions provided below. All financial references are denominated in U.S. dollars, unless otherwise noted. Company Highlights for the Three Months Ended March 31, 2025:4th consecutive quarter of carbon credit sales revenue with net cash proceeds of $0.8 million from Vietnam water purifier carbon credit monetizationQ1 2025 normal course issuer bid repurchases of...

Revenue Surges 246% Year-Over-Year as Newton Motion Shaft Adoption Accelerates Across Major Tours CAMARILLO, Calif., May 15, 2025 (GLOBE NEWSWIRE) — via IBN – NEWTON GOLF Company (NASDAQ: NWTG) (“Newton Golf” or the “Company”), a technology-forward golf company delivering physics-based performance innovations for players at every level, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 HighlightsRevenue increased 246% to $1.2 million, compared to $350,000 in Q1 2024Gross profit rose 348% to $852,000, up from $190,000 in the prior-year periodGross margin expanded to 70%, up from 54% a year agoNet loss of $0.5 million, or ($0.55) per share, compared to a net loss of $1.2 million, or ($24.85) per share in Q1 2024.Note: The Q1 2024 per-share figure reflects the pre-uplisting share...

VANCOUVER, British Columbia, May 15, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces financial results for the first quarter 2025. First Quarter 2025 Highlights:Total revenues for the first quarter of 2025 were $1.13 million, up 92% compared to $591,379 for the first quarter of 2024 primarily due to acquisitions and organic growth. ZenaTech’s new Drone as a Service or DaaS segment grew from completing two acquisitions of land survey drone servicing companies ─ Oregon-based Weddle Surveying and Florida-based KJM Land Surveying. The Company also signed five LOIs (Letter of Intent) for additional acquisitions during the quarter. The...

MIAMI, May 15, 2025 (GLOBE NEWSWIRE) — Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), a vertically integrated power infrastructure company focused on developing cutting-edge data centers for high-performance computing, is pleased to provide a summary of the Company’s unaudited financial results for the three-month period ended March 31, 2025 (all amounts in U.S. dollars, unless otherwise indicated), and a 2025 year-to-date update on operations. The Company’s unaudited consolidated financial statements and management’s discussion and analysis (“MD&A”) for the three-month period ended March 31, 2025, have been filed and made accessible under the Company’s continuous disclosure profile on SEDAR+ at www.sedarplus.ca and are also available on the SEC’s EDGAR website at www.sec.gov/edgar. Highlights...

– Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagenezamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adultand pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) – – U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) – – Entered into sales agreement for priority review voucher (PRV) for $155 million – CLEVELAND, May 15, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results and business highlights for the first quarter of 2025 and shared recent operational progress. “ZEVASKYN’s approval just a few weeks ago is a landmark achievement for recessive dystrophic epidermolysis bullosa patients and...

OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include:Total revenue was $15.9 million, 4% lower than the first quarter of 2024.   Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024. Gross margin was 43.1% compared to 44.0% during the first quarter of 2024. Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during the same period last year. Basic earnings per share and diluted earnings per share were $0.22 and $0.20, respectively, compared to $0.23 and...

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter. Management Commentary: “Starting 2025 with positive momentum, we are proud to report our first profitable quarter—a milestone that reflects our strategic focus and operational discipline. With this solid foundation, we are now positioned to focus on scaling our Canadian operations, international expansion, and advancing of our R&D pipeline and intellectual property” stated Aras Azadian, CEO of Avicanna. Q1 2025 Financial Highlights: First...

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of March 31, 2025, expected to fund operations into the second half of 2027 Company to host conference call at 8:30 a.m. ET today WAYNE,...